Pfizer grabs leg up in pursuit of rare disease drug win

The FDA has given pharma giant Pfizer ($PFE) a fast-track review of its drug tafamidis meglumine for treating the rare disease known as transthyretin familial amyloid polyneuropathy, meaning the agency is set to decide on the drugmaker's application for approval by June, The Wall Street Journal reported. The fast-track designation boosts Pfizer's move into the rare disease drug segment, which has attracted lots of attention from the company and its Big Pharma counterparts because of its blockbuster prospects. Pfizer picked up tafamidis meglumine via its FoldRx buyout in 2010. Report

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.